Should we consider progression-free survival benefits enough for drug approvals in locally advanced cervical cancer?

Journal article

Peer reviewed

Bradley J. Monk, Robert L. Coleman, Krishnansu S. Tewari, Leslie M. Randall, Bhavana Pothuri, Brian M. Slomovitz and Thomas J. Herzog

Gynecologic oncology, Vol.189, pp.146-147

10/01/2024

PMID: 39142061

Abstract

Life Sciences & Biomedicine

Obstetrics & Gynecology

Oncology

Science & Technology

1 Record Views

Title: Should we consider progression-free survival benefits enough for drug approvals in locally advanced cervical cancer?
Creators: Bradley J. Monk - Florida Cancer Specialists & Research Institute
Robert L. Coleman - Texas Oncology
Krishnansu S. Tewari - University of California, Irvine
Leslie M. Randall - Virginia Commonwealth University
Bhavana Pothuri - Gynecologic Oncology Group
Brian M. Slomovitz - Mount Sinai Medical Center
Thomas J. Herzog - University of Cincinnati
Publication Details: Gynecologic oncology, Vol.189, pp.146-147
Publisher: Elsevier
Number of pages: 2
Identifiers: 991006113378802656
Academic Unit: Obstetrics & Gynecology
Language: English
Resource Type: Journal article